Shire Targets Mylan In Latest Suit Over Generic Vyvanse

Law360, New York (July 15, 2011, 5:37 PM EDT) -- Shire PLC sued Mylan Inc. on Thursday in New York over a planned generic version of the attention deficit hyperactivity disorder treatment Vyvanse, marking the company's latest effort to protect the market for its top selling product.

Shire filed a complaint accusing Mylan of infringing the patent covering the formula for Vyvanse, U.S. Patent Number 7,700,561, after the company moved to get approval from the U.S. Food and Drug Administration for its own version of the drug.

“The acts of infringement ... will cause Shire irreparable...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.